To investigate the clinical efficacy of astragalus injection combined with budesonid inhaling in patients with bronchial asthma(BA)and provide clinical evidences for BA treatment. Methods: From 2010/6 to 2013/6, we collected 94 BA patients in our hospital and divided them into two groups randomly, 47 cases in control group and 47 cases in observation group. The control group were treated with conventional therapy with budesonid inhaling; the observation group were treated with conventional therapy as well as budesonid inhaling and astragalus injection. Clinical effects, pulmonary function, and levels of inflammatory factors were observed and compared. Results: The observation group had a therapeutic efficiency ratio(TER)of 97.9% which was significantly higher than the control group(83.0%), and the difference was statistically significant(P<0.05). The VC, FEV1, FEV1/FVC, and the levels of IL-6, IL-10 and IL-17 of the two groups were both significantly improved respectively after treatments(P<0.05). However, those of the observation group had greater improvement than those of the control group after treatments(P<0.05). Conclusion: As it can help promote the pulmonary function and decrease the inflation factors in serum, astragalus injection combined with budesonid inhaling for BA treatment proves to be effective, which is worthy of study and further application in clinical treatment. Our study provides new evidences for clinical therapy of BA.